Olema Pharmaceuticals (OLMA) Accumulated Expenses (2020 - 2026)

Olema Pharmaceuticals (OLMA) has 7 years of Accumulated Expenses data on file, last reported at $2.2 million in Q1 2026.

• On a quarterly basis, Accumulated Expenses rose 202.06% year-over-year to $2.2 million in Q1 2026; TTM through Mar 2026 was $2.2 million, a 202.06% increase from a year earlier, with the FY2025 full-year figure at $8.3 million, up 45.79% from the prior year.
• Accumulated Expenses for Q1 2026 stood at $2.2 million, down from $8.3 million in the prior quarter.
• Over the last five years, Accumulated Expenses for OLMA reached as high as $12.8 million in Q3 2023 and fell as low as $184000.0 in Q2 2022.
• Historically, Accumulated Expenses has averaged $2.7 million across 5 years, with a median of $729000.0 in 2025.
• Across the five-year window, Accumulated Expenses sank 92.11% in 2022 and jumped 3061.33% in 2023, its largest moves.
• Year by year, Accumulated Expenses stood at $296000.0 in 2022, then jumped by 1746.28% to $5.5 million in 2023, then gained by 3.59% to $5.7 million in 2024, then jumped by 45.79% to $8.3 million in 2025, then sank by 73.32% to $2.2 million in 2026.
• Per Business Quant data, the three most recent Accumulated Expenses figures were $2.2 million in Q1 2026, $8.3 million in Q4 2025, and $406000.0 in Q3 2025.